BMO Capital Downgrades Arena Pharma (ARNA) to Market Perform Ahead of PDUFA

June 25, 2012 7:18 AM EDT
Get Alerts ARNA Hot Sheet
Price: $1.37 +0.74%

Rating Summary:
    5 Buy, 10 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ARNA Now!
Join SI Premium – FREE
BMO Capital downgraded momentum stock Arena Pharma (NASDAQ: ARNA) from Outperform to Market Perform while maintaining their $10 price target.

Shares of ARNA have surged into the 6/27 PDUFA date for obesity drug Lorcaserin, which an FDA panel backed 18 to 4 in May.

The firm said Lorcaserin approval is now priced in, while monitoring requirements will be key.

For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.

Shares of Arena Pharma closed at $9.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Downgrades, Hot Downgrades, Momentum Movers

Related Entities

BMO Capital

Add Your Comment